By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem webinar to explore stirred bed technology in scale oligomer production
Bubendorf, Switzerland: – Bachem, the leading CDMO will use its latest webinar to explore possibilities of extending its innovative stirred bed reactor technology proven in peptides production to the manufacture of oligonucleotides as well.
The free-to-register webinar ‘Scalable Oligonucleotide Manufacture With Stirred-Bed Technology’ will be hosted via the Zoom platform on Wednesday, May 24, 2023, commencing at 1700hrs CET (UTC +2) and will last approximately one hour. Registration is available online (see Resources).
Applying peptide lessons to oligos
The session will cover lessons learned over decades of experience in Bachem’s application to uses of stirred-bed technology (SBT) reactors for making peptides, and its recent investigations into their use in oligomer production at metric ton scale.
Discussion will provide insights into case studies, Bachem SBT capabilities ranging from R&D to large scale production projects, and its typical CMC activities for scale-up.
Crucially, the webinar will also review the distinct advantages that stirred-bed solid-phase oligonucleotide synthesis (SPOS) has over classical fixed-bed SPOS.
Principal speaker will be Dr. Daniel Samson, Bachem Vice President who heads its Oligonucleotides Unit. Dr. Samson’s 15 years of industry experience includes ‘tides process R&D, manufacturing and CMC development. He leads Bachem’s oligonucleotide unit, having previously been responsible for API Manufacturing including large-scale solid phase peptide and oligonucleotide synthesis, downstream operations, and CMC activities.
The webinar will also hear from Dr. Chris McGee, Bachem Vice President who head Global Business Development (BD) and based in California, having previously been Senior Director of BD for Bachem Americas, where he was at the forefront of communications related to the development and manufacturing of new peptide and oligonucleotide-based chemical entities with his team of peptide experts in the field.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
Click on Bachem webinar: ‘Scalable Oligonucleotide Manufacture With Stirred-Bed Technology’ to register for the event.
Click on Bachems News to see latest News & Events.